Dear Dr Gallina,

It was a pleasure meeting you and your team on the 26th of June.

We appreciated the conversation and listened to your feedback on our initial pricing proposal. We share the same desire to bring to the European citizens a safe and effective vaccine at scale as soon as possible at a fair and reasonable price.

You may have also seen that on July 1, Pfizer and BioNTech issued a press release to announce early positive clinical data regarding the ongoing Phase 1/2 study we discussed with you for the most advance of our four investigational vaccines, the nucleoside-modified messenger RNA (mRNA) candidate, BNT162b1. The manuscript describing the preliminary clinical data is available now on the medRxiv preprint server at https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1 and is concurrently undergoing scientific peer-review for potential publication. Overall, the preliminary data demonstrated that BNT162b1 could be administered in a dose that was well tolerated and generated dose-dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. Local reactions and systemic events after immunization with 10 µg and 30 µg of BNT162b1 were dose-dependent, generally mild to moderate, and transient. No serious adverse events were reported. Further data from the ongoing Phase 1/2 clinical trial of four vaccine candidates will enable selection of a lead candidate and dose level for a large, global Phase 2b/3 safety and efficacy study that may begin as early as July 2020.
Based on these additional insights and to address your feedback, we are open to continuing discussion about our pricing approach. We are very much looking forward to our next meeting(s) to identify with you a fair and reasonable price and share additional information we now have from our development program.

In the meantime, if you have any questions, please do not hesitate to contact me.

Best regards,